MedPath
HSA Approval

TELMISARTAN-DRLA TABLETS 80MG

SIN17074P

TELMISARTAN-DRLA TABLETS 80MG

TELMISARTAN-DRLA TABLETS 80MG

August 30, 2024

ZYFAS PHARMA PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantZYFAS PHARMA PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

C09CA07

Manufacturer Information

ZYFAS PHARMA PTE. LTD.

DR. REDDY'S LABORATORIES LTD. - FTO 2

Active Ingredients

TELMISARTAN

80.000mg

Telmisartan

Documents

Package Inserts

TELMISARTAN-DRLA TABLET PI.pdf

Approved: August 30, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

TELMISARTAN-DRLA TABLETS 80MG - HSA Approval | MedPath